USA flag logo/image

An Official Website of the United States Government

An Imaging Marker for Parkinson's Disease

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
61141
Program Year/Program:
2003 / SBIR
Agency Tracking Number:
NS043826
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Molecular Neuroimaging, L.l.c.
60 TEMPLE STREET, SUITE 8A NEW HAVEN, CT -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2003
Title: An Imaging Marker for Parkinson's Disease
Agency: HHS
Contract: 2R44NS043826-02
Award Amount: $749,655.00
 

Abstract:

DESCRIPTION (provided by applicant): The development of disease modifying agents in Parkinson's disease has rapidly expanded the need for in vivo markers for diagnosis and monitoring disease progression. Dopamine transporter (DAT) imaging offers the promise of an objective measure of dopaminergic degeneration allowing for identification of changes in the brain that occur early in the illness, prior to clinical diagnosis. The primary goal of this project is to examine the sensitivity and specificity of DAT imaging using [123I]beta-CIT and SPECT imaging as a diagnostic marker in subjects with suspected PD or PS. We have successfully completed the Phase I pilot study for this project and have utilized these data and experience in designing this Phase II SBIR proposed protocol. The overall study design is to recruit subjects with suspected PD from participating community neurologists and compare the baseline diagnoses of the community neurologists, movement disorders experts and dopamine transporter imaging to a 'gold standard' clinical diagnosis assigned by a movement disorder expert at 12 months follow-up. The DAT imaging diagnosis will be compared to the 'gold standard' clinical diagnosis to determine the sensitivity of [123I]beta-CIT and SPECT imaging as a diagnostic marker in PD and PS. This project is a crucial step to begin to establish [123I]beta-CIT and SPECT imaging as an objective diagnostic biomarker prior to a definitive diagnosis in patients with early parkinsonian symptoms.

Principal Investigator:

Danna L. Jennings
2034014333
DJENNINGS@MNIMAGING.COM

Business Contact:

Jack Maiotti
2034014351
JMARIOTTI@MNIMAGING.COM
Small Business Information at Submission:

MOLECULAR NEUROIMAGING, LLC
MOLECULAR NEUROIMAGING, LLC 60 TEMPLE ST, STE 8A NEW HAVEN, CT 06510

EIN/Tax ID: 061594851
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No